Aquestive Therapeutics will present at the Piper Sandler Healthcare Conference on December 2, 2026, in New York City.
Quiver AI Summary
Aquestive Therapeutics, Inc. announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City, where President and CEO Daniel Barber will present on December 2 at 10:30 am ET. The company will also conduct one-on-one meetings with investors that day, and a webcast of the presentation will be available on their website with a replay offered for 30 days. Aquestive is focused on advancing innovative medicines, including the Anaphylm™ sublingual film for severe allergic reactions and the AQST-108 topical gel for dermatological conditions, leveraging its proprietary PharmFilm® technology. Additionally, the press release includes forward-looking statements about the company's product development and associated risks.
Potential Positives
- Aquestive Therapeutics will participate in the Piper Sandler 38th Annual Healthcare Conference, enhancing its visibility among investors and industry stakeholders.
- CEO Daniel Barber will present at the conference, providing a platform to discuss the company's product pipeline and strategic direction.
- The company is advancing its proprietary product candidates, including Anaphylm™ and AQST-108, showcasing its commitment to innovation in treating severe allergic reactions and dermatological conditions.
Potential Negatives
- The press release highlights significant risks and uncertainties related to the company's product development activities, specifically mentioning potential delays and changes to the timing, cost, and success of clinical trials for key products, such as Anaphylm™ and AQST-108, which could negatively impact investor confidence.
- The forward-looking statements contained in the press release may cause concern for investors as they emphasize that actual results may differ materially from the company's expectations, indicating a lack of certainty about future performance.
FAQ
What is the date of the Piper Sandler Healthcare Conference?
The Piper Sandler 38th Annual Healthcare Conference is from December 1-3, 2026.
Who will represent Aquestive at the conference?
Aquestive President and CEO Daniel Barber will be presenting at the conference.
When is Aquestive's presentation scheduled?
Aquestive's presentation is scheduled for Wednesday, December 2, 2026, at 10:30 am ET.
Where can I watch the presentation webcast?
The webcast will be available under the “Events and Presentations” page on the Company’s website.
What are Aquestive's key products?
Aquestive develops oral films and epinephrine prodrugs for allergies and dermatological conditions, including Anaphylm™ and AQST-108.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AQST Insider Trading Activity
$AQST insiders have traded $AQST stock on the open market 10 times in the past 6 months. Of those trades, 2 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $AQST stock by insiders over the last 6 months:
- DANIEL BARBER (President and CEO) has made 0 purchases and 6 sales selling 125,000 shares for an estimated $537,456.
- JULIE KROP sold 25,000 shares for an estimated $125,392
- RICHARD J DALY has made 2 purchases buying 28,025 shares for an estimated $99,330 and 0 sales.
- SHERRY KORCZYNSKI (Chief Commercial Officer) sold 8,750 shares for an estimated $45,675
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AQST Revenue
$AQST had revenues of $7.6M in Q3 2026. This is a decrease of -40.99% from the same period in the prior year.
You can track AQST financials on Quiver Quantitative's AQST stock page.
You can access data on AQST stock through the Quiver Quantitative API.
$AQST Hedge Fund Activity
We have seen 85 institutional investors add shares of $AQST stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. added 1,750,000 shares (+700.0%) to their portfolio in Q3 2026, for an estimated $8,102,500
- HRT FINANCIAL LP added 1,456,864 shares (+422.5%) to their portfolio in Q3 2026, for an estimated $6,745,280
- PROPEL BIO MANAGEMENT, LLC removed 1,163,674 shares (-80.7%) from their portfolio in Q3 2026, for an estimated $5,387,810
- NUVEEN, LLC removed 937,472 shares (-77.1%) from their portfolio in Q3 2026, for an estimated $4,340,495
- D. E. SHAW & CO., INC. removed 903,557 shares (-96.0%) from their portfolio in Q2 2026, for an estimated $3,758,797
- BALYASNY ASSET MANAGEMENT L.P. removed 744,536 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $3,447,201
- WASATCH ADVISORS LP removed 737,670 shares (-53.2%) from their portfolio in Q3 2026, for an estimated $3,415,412
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AQST Analyst Ratings
Wall Street analysts have issued reports on $AQST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/24/2026
To track analyst ratings and price targets for $AQST, check out Quiver Quantitative's $AQST forecast page.
Full Release
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will participate in the Piper Sandler 38 th Annual Healthcare Conference December 1-3, 2026, in New York City.
Aquestive President and CEO Daniel Barber will be presenting on Wednesday, December 2, 2026, at 10:30 am ET. The Company will also be hosting one-on-ones with investors that day.
A webcast of the presentation will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics
Aquestive is a biopharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive develops proprietary pharmaceutical products and operates U.S.-based manufacturing facilities in Indiana, with its headquarters in New Jersey. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive’s AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidates, including Anaphylm™ (dibutepinephrine) sublingual film and AQST-108 (epinephrine prodrug) topical gel, through clinical development and approval by the U.S. Food and Drug Administration (FDA) for the respective targeted indications. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm and AQST-108, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm
®
and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
[email protected]